Compare · RLX vs USNA
RLX vs USNA
Side-by-side comparison of RLX Technology Inc. (RLX) and USANA Health Sciences Inc. (USNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RLX and USNA operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- RLX is the larger of the two at $3.07B, about 7.8x USNA ($395.1M).
- Over the past year, RLX is down 15.4% and USNA is down 31.6% - RLX leads by 16.3 points.
- USNA has hit the wire 2 times in the past 4 weeks while RLX has been quiet.
- USNA has more recent analyst coverage (3 ratings vs 2 for RLX).
- Company
- RLX Technology Inc.
- USANA Health Sciences Inc.
- Price
- $1.99+0.76%
- $21.47-2.76%
- Market cap
- $3.07B
- $395.1M
- 1M return
- -2.22%
- +7.86%
- 1Y return
- -15.35%
- -31.61%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 2
- Recent ratings
- 2
- 3
RLX Technology Inc.
RLX Technology Inc., together with its subsidiaries, researchers, develops, manufactures, distributes, and sells e-vapor products in the People's Republic of China. It serves RELX branded partner stores and other retail outlets through distributors. RLX Technology Inc. was founded in 2018 and is based in Beijing, China.
USANA Health Sciences Inc.
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products, which provide macro-nutrition. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. The company has a research collaboration agreement with Beijing University of Chinese Medicine for research in the field of traditional Chinese medicine. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.
Latest RLX
- SEC Form 6-K filed by RLX Technology Inc.
- RLX Technology Announces Unaudited First Quarter 2026 Financial Results
- RLX Technology to Report First Quarter 2026 Financial Results on May 20, 2026
- RLX Technology Files 2025 Annual Report on Form 20-F
- SEC Form 20-F filed by RLX Technology Inc.
- SEC Form 3 filed by new insider Wang Ying Kate
- SEC Form 3 filed by new insider Jiang Long
- SEC Form 3 filed by new insider Xi Youmin
- SEC Form 3 filed by new insider Wen Yilong
- SEC Form 3 filed by new insider Lu Chao
Latest USNA
- USANA Schedules Second Quarter 2026 Earnings Release and Conference Call
- Kevin Guest: World Cup Determination Shows the Power of Grit, Preparation, Persistence
- CHIEF COMMERCIAL OFFICER Neidig Brent sold $97,304 worth of shares (5,002 units at $19.45), closing all direct ownership in the company (SEC Form 4)
- CHIEF COMMERCIAL OFFICER Neidig Brent sold $50,465 worth of shares (2,511 units at $20.10), decreasing direct ownership by 33% to 5,002 units (SEC Form 4)
- USANA Celebrates 10 Years of Making the World a Better Place During World Service Week
- SEC Form 11-K filed by USANA Health Sciences Inc.
- CHIEF PEOPLE OFFICER Jones Paul A. sold $102,878 worth of shares (5,561 units at $18.50), closing all direct ownership in the company (SEC Form 4)
- USANA's Celavive Contouring Face & Neck Crème Named Among Canada's Top Skincare Products
- USANA Earns Dual Best of State Honors for Product Innovation and Development
- Director Fleming John Turman sold $43,928 worth of shares (2,450 units at $17.93), decreasing direct ownership by 37% to 4,230 units (SEC Form 4)